Annexin A5 Purification Using Non-Ionic Detergents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing therapeutic-grade Annexin A5 protein are inefficient, costly, and unable to scale up for commercial production due to high endotoxin contamination and low yield, particularly when using recombinant E. coli host cells, which require multiple centrifugation steps and result in low purity.
Innovation Solution
A process involving the use of non-ionic detergents like Tween80 in homogenization buffers to prevent endotoxin binding, combined with anion exchange and heparin affinity chromatography steps to achieve high purity and yield without the need for centrifugation, allowing for efficient large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multiple centrifugation steps are used to purify Annexin A5, then purity may be improved, but productivity decreases and manufacturing cost increases
Solution Approach 1:
The patent extracts and removes endotoxin from the purification process by using non-ionic detergents that specifically bind to and eliminate endotoxin, separating this harmful component from the Annexin A5 purification steps. This allows simplification of the overall process while maintaining purity requirements.
Solution Approach 2:
The patent changes the chemical parameters of the homogenization buffer by incorporating non-ionic detergents (such as Tween 80) at specific concentrations, which alters the binding properties of endotoxin and prevents its interaction with Annexin A5 during purification, thereby simplifying the process.
2Productivity
If recombinant E. coli host cells are used for production, then productivity increases, but harmful factors (endotoxin contamination) worsen
Solution Approach 1:
The patent introduces non-ionic detergents as intermediary substances that mediate between the endotoxin and the purification process. These detergents bind to endotoxin molecules, preventing them from contaminating the Annexin A5 product while allowing the E. coli host cells to continue providing high productivity.
Solution Approach 2:
The patent converts the harmful endotoxin into a beneficial purification target by using non-ionic detergents that specifically bind to endotoxin. The endotoxin, which was previously a contaminant to be removed, becomes a substance that can be selectively captured and removed in a single step, improving both productivity and product quality.
3Ease of manufacture
If conventional homogenization buffers are used, then ease of manufacture is maintained, but harmful factors (endotoxin binding) worsen
Solution Approach 1:
The patent modifies the chemical composition parameters of the homogenization buffer by adding non-ionic detergents at optimized concentrations. This parameter change prevents endotoxin binding while maintaining the simplicity and ease of manufacture of the buffer system.
Solution Approach 2:
The patent performs preliminary action by pre-incubating the homogenization buffer with non-ionic detergents before cell lysis. This preliminary step ensures that endotoxin is already bound to the detergent when cell rupture occurs, preventing endotoxin release and contamination throughout the subsequent purification process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables the production of pharmaceutical-grade Annexin A5 with improved yield and purity, reducing endotoxin contamination and eliminating the need for costly and time-consuming centrifugation steps, facilitating commercial-scale production.
Implementation Method 1
The use of non-ionic detergents such as Tween80 in homogenisation buffers is known to prevent binding of endotoxin to Annexin A5
Implementation Method 2
anion exchange and heparin affinity chromatography steps to achieve high purity
Implementation Method 3
anion exchange and heparin affinity chromatography steps to achieve high purity and yield
Data Source
AI summary
The present invention provides a process for the recovery and/or purification of a recombinantly expressed intracellular protein comprising the sequence of Annexin A5 (AnxA5) from an endotoxin-producing host cell with a cell wall, wherein the process comprises releasing the intracellular protein from the host cell, characterised in that the step of releasing the intracellular AnxA5 protein is conducted in the presence of a homogenisation buffer comprising non-ionic detergent, and preferably wherein the process does not include any centrifugation steps for the recovery and/or purification of the AnxA5 protein after its release from the host cell and/or in which the AnxA5 protein remains in solution throughout the process except when temporarily bound to any chromatographic resins.